Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

18.07 +0.28 (+1.57%)
Streaming Delayed Price Updated: 3:26 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug
The FDA will review Travere's drug by mid-November for a kidney disease. 
Via Investor's Business Daily
FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review
The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of... 
Via Benzinga
Here's Why Travere Therapeutics Shares Are Rising Today
Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million. 
Via Benzinga
Earnings Outlook For Retrophin
Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Retrophin will... 
Via Benzinga
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared... 
Via Benzinga
Travere Therapeutics: Q4 Earnings Insights
Travere Therapeutics (NASDAQ:TVTX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Travere Therapeutics's Earnings: A Preview
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic Disorder
Travere Therapeutics Inc (NASDAQ: TVTX) reported topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase for classical homocystinuria (HCU).... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Bellerophon Therapeutics (NASDAQ: 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
PleasrDAO Aint Nothing To F*** With: Wu Tang Clan Album Once Owned By Shkreli Has Been Purchased
From the slums of Shaolin, Wu-Tang Clan strikes again. An exclusive album made by the legendary hip-hop group is back in the news ... 
Via Benzinga
8 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
From Vifor Pharma Group
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Larimar Therapeutics (NASDAQ: 
Via Benzinga
See Why Travere Therapeutics Stock Moving Higher On Tuesday
Travere Therapeutics Inc (NASDAQ: TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS). See:... 
Via Benzinga
Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0.02% to 4,468.88. The U.S. has the... 
Via Benzinga
Topics Stocks
60 Biggest Movers From Yesterday
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of... 
Via Benzinga
Here's Why Travere Therapeutics Stock Is Climbing Today
Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.